These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 954793)

  • 21. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens.
    Edmonson JH; McCormack GM; Wieand HS; Kugler JW; Krook JE; Stanhope CR; Everson LK; Laurie JA; Ebbert LP; Malkasian GD
    J Natl Cancer Inst; 1989 Oct; 81(19):1500-4. PubMed ID: 2674460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens.
    Vogl SE; Pagano M; Kaplan BH; Greenwald E; Arseneau J; Bennett B
    Cancer; 1983 Jun; 51(11):2024-30. PubMed ID: 6404547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. VM26 (NSC-122819): a clinical study in advanced cancer of the lung and ovary.
    Samson MK; Baker LH; Talley RW; Fraile RJ
    Eur J Cancer (1965); 1978 Dec; 14(12):1395-9. PubMed ID: 216556
    [No Abstract]   [Full Text] [Related]  

  • 24. [Results of a cyclophosphamide therapy in genital and mammary carcinomas].
    Naumann R
    Zentralbl Gynakol; 1970 May; 92(22):700-2. PubMed ID: 5284155
    [No Abstract]   [Full Text] [Related]  

  • 25. A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancer.
    Edwards CL; Herson J; Gershenson DM; Copeland LJ; Wharton JT
    Gynecol Oncol; 1983 Apr; 15(2):261-77. PubMed ID: 6403413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.
    Hannigan EV; Green S; Alberts DS; O'Toole R; Surwit E
    Oncology; 1993 Nov; 50 Suppl 2():2-9. PubMed ID: 8233297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose cyclophosphamide in patients with operable breast cancer: recombinant human GM-CSF ameliorates drug-induced leukopenia and thrombocytopenia.
    Bregni M; Siena S; Ravagnani F; Bonadonna G; Gianni AM
    Haematologica; 1990; 75 Suppl 1():95-8. PubMed ID: 2190885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
    Piccart MJ; Bertelsen K; James K; Cassidy J; Mangioni C; Simonsen E; Stuart G; Kaye S; Vergote I; Blom R; Grimshaw R; Atkinson RJ; Swenerton KD; Trope C; Nardi M; Kaern J; Tumolo S; Timmers P; Roy JA; Lhoas F; Lindvall B; Bacon M; Birt A; Andersen JE; Zee B; Paul J; Baron B; Pecorelli S
    J Natl Cancer Inst; 2000 May; 92(9):699-708. PubMed ID: 10793106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of cepharanthin on leukopenia and thrombocytopenia caused by CDDP-ACR-CPA therapy of ovarian cancer].
    Ushiki N; Jobo T; Shimoda T; Kuramoto H; Arai M
    Gan To Kagaku Ryoho; 1988 Sep; 15(9):2701-6. PubMed ID: 3415268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer. A randomized clinical study.
    Bolis G; Bortolozzi G; Carinelli G; D'Incalci M; Gramellini F; Morasca L; Mangioni C
    Cancer Chemother Pharmacol; 1980; 4(2):129-32. PubMed ID: 7389058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proceedings: Evaluation of combination vs. sequential cytotoxic chemotherapy in the treatment of advanced breast cancer.
    Baker LH; Vaughn CB; al-Sarraf M; Reed ML; Vaitkevicius VK
    Cancer; 1974 Feb; 33(2):513-8. PubMed ID: 4812768
    [No Abstract]   [Full Text] [Related]  

  • 33. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
    Dinkic C; Eichbaum M; Schmidt M; Grischke EM; Gebauer G; Fricke HC; Lenz F; Wallwiener M; Marme F; Schneeweiss A; Sohn C; Rom J
    Gynecol Oncol; 2017 Aug; 146(2):279-284. PubMed ID: 28528917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pilot study evaluating 1,3-bis(2-chloroethyl)-1-nitrosourea in the treatment of advanced ovarian carcinoma.
    Jorgensen EO; Malkasian GD; Webb MJ; Hahn RG
    Am J Obstet Gynecol; 1973 Jul; 116(6):769-70. PubMed ID: 4577261
    [No Abstract]   [Full Text] [Related]  

  • 35. Carboplatin/cyclophosphamide combination chemotherapy for advanced ovarian cancer.
    Teeling M; Hayes Y; Fitzmaurice B; McGing P; Carney DN
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):102-6. PubMed ID: 1411620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy.
    El-Husseiny K; Motawei H; Ali MS
    Int J Gynecol Cancer; 2016 Mar; 26(3):437-42. PubMed ID: 26825824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
    Jodrell DI; Egorin MJ; Canetta RM; Langenberg P; Goldbloom EP; Burroughs JN; Goodlow JL; Tan S; Wiltshaw E
    J Clin Oncol; 1992 Apr; 10(4):520-8. PubMed ID: 1548516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Endoxan in ovarian cancer].
    Campodónico I; Soldati A; Rodríguez A
    Rev Chil Obstet Ginecol; 1974; 39(3):87-9. PubMed ID: 4620179
    [No Abstract]   [Full Text] [Related]  

  • 39. Advanced ovarian cancer: a prospective randomised trial of chlorambucil versus combined cyclophosphamide and cis-diamminedichloroplatinum.
    Bell DR; Woods RL; Levi JA; Fox RM; Tattersall MH
    Aust N Z J Med; 1982 Jun; 12(3):245-9. PubMed ID: 7052040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A pilot trial of high dose CEP (cyclophosphamide, epirubicin, cis-platinum) therapy in patients with advanced and recurrent ovarian cancer].
    Hiura M; Ogawa M; Nozawa S; Kudo R; Kuwabara Y; Takahashi T; Takayama M; Tateno M; Ohashi Y; Yakushiji M
    Gan To Kagaku Ryoho; 2000 Apr; 27(4):585-91. PubMed ID: 10791001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.